Pharmacotherapy for Alzheimer's disease: progress and prospects (Q34866800)

5 August 2017

1 reference

title

Pharmacotherapy for Alzheimer's disease: progress and prospects (English)

1 reference

5 August 2017

0 references

0 references

Alan M Palmer

1

1 reference

5 August 2017

publication date

1 September 2002

1 reference

Trends in Pharmacological Sciences

5 August 2017

published in

1 reference

5 August 2017

volume

23

1 reference

5 August 2017

issue

9

1 reference

5 August 2017

page(s)

426-433

1 reference

Treatment of Alzheimer's disease

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

Imaging of onset and progression of Alzheimer's disease with voxel-compression mapping of serial magnetic resonance images.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

Cortical connections and the pathology of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

The autonomic higher order processing nuclei of the lower brain stem are among the early targets of the Alzheimer's disease-related cytoskeletal pathology.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

Age-specific incidence of Alzheimer's disease in a community population

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

The cholinergic hypothesis of Alzheimer's disease: a review of progress

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

Trans-synaptic stimulation of cortical acetylcholine and enhancement of attentional functions: a rational approach for the development of cognition enhancers

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

Use of acetylcholinesterase inhibitors in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

Is there a rationale for the use of acetylcholinesterase inhibitors in the therapy of Alzheimer's disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

Neurochemical studies of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

Cortical pyramidal neurone loss may cause glutamatergic hypoactivity and cognitive impairment in Alzheimer's disease: investigative and therapeutic perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

The role of mammalian ionotropic receptors in synaptic plasticity: LTP, LTD and epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

Synaptic pathology in Alzheimer's disease: relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the ApoE4 allele.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

Facilitative Effects of the Ampakine CX516 on Short-Term Memory in Rats: Enhancement of Delayed-Nonmatch-to-Sample Performance

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

Cognitive and behavioral heterogeneity in Alzheimer's disease: seeking the neurobiological basis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

Natural history of behavioural changes and psychiatric symptoms in Alzheimer's disease. A longitudinal study

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

Serotonin and motor activity

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

Role of locus coeruleus in attention and behavioral flexibility

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

Antidepressants: past, present and future

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

Noradrenergic changes, aggressive behavior, and cognition in patients with dementia

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

New frontiers in Alzheimer's disease genetics

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

Alzheimer's disease: molecular concepts and therapeutic targets

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

Preclinical and clinical challenges in the development of disease-modifying therapies for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

Gamma-secretase: never more enigmatic

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

Presenilins as therapeutic targets for the treatment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

Need for vaccine stocks questioned

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

Tau protein isoforms, phosphorylation and role in neurodegenerative disorders11These authors contributed equally to this work

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

The molecular genetics of the tauopathies

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

The activity of the pentose phosphate pathway is increased in response to oxidative stress in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

Inherent abnormalities in energy metabolism in Alzheimer disease. Interaction with cerebrovascular compromise

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

Cellular and molecular mechanisms underlying perturbed energy metabolism and neuronal degeneration in Alzheimer's and Parkinson's diseases.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

Cholesterol modulation as an emerging strategy for the treatment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

Cholesterol, A beta and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

A comparative assessment of the efficacy and side-effect liability of neuroprotective compounds in experimental stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

Neuroprotective and symptomatological action of memantine relevant for Alzheimer's disease--a unified glutamatergic hypothesis on the mechanism of action

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

Neuropathological stageing of Alzheimer-related changes

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

Excitatory amino acid-releasing and cholinergic neurones in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

Non-Alzheimer-type pattern of brain cholineacetyltransferase reduction in dominantly inherited olivopontocerebellar atrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

Cholinergic markers in elderly patients with early signs of Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

The decline in synapses and cholinergic activity is asynchronous in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the cholinergic deficits.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

Neurochemical studies of early-onset Alzheimer's disease. Possible influence on treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

Brain choline acetyltransferase and mental function in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

Alzheimer's disease: a correlative study

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

Effect of rivastigmine on scopolamine-induced memory impairment in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

Effects of the potassium channel blockers, apamin and 4-aminopyridine, on scopolamine-induced deficits in the delayed matching to position task in rats: a comparison with the cholinesterase inhibitor E2020

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

Dissociation between cognitive and motor/motivational deficits in the delayed matching to position test: effects of scopolamine, 8-OH-DPAT and EAA antagonists.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

Scopolamine and the control of attention in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

Place navigation in rats is impaired by lesions of medial septum and diagonal band but not nucleus basalis magnocellularis.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

Selective fimbria lesions impair acquisition of working and reference memory of rats in a complex spatial discrimination task

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

The basal forebrain-cortical cholinergic system: interpreting the functional consequences of excitotoxic lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

Cholinesterase inhibitors for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

Acetylcholine affects the spatial scale of attention: evidence from Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2802%2902056-4

7 January 2021

10.1016/S0165-6147(02)02056-4

Identifiers

DOI

1 reference

5 August 2017

1 reference